The course of pregnancy and delivery in patients with prolactinoma during treatment with cabergoline

Larisa Dzeranova; Daria Skuridina; Svetlana Vorotnicova; Ekaterina Pigarova

The course of pregnancy and delivery in patients with prolactinoma during treatment with cabergoline

2016

Larisa Dzeranova | Daria Skuridina | Svetlana Vorotnicova | Ekaterina Pigarova

Objectives: To assess the risk of pregnancy and fetal pathology in patients with prolactin-secreting tumors treated with cabergoline in the early stages of gestation.Materials and methods: The study included 24 patients in the age from 24 to 38 years old with prolactin-secreting tumors, become pregnant during therapy with cabergoline (Dostinex). A retrospective analysis of the course and outcomes of 33 pregnancies based on available medical records and questioning of the patients data.Results: Of the 33 pregnancies resulted in births 26 (78.8%), registered a spontaneous miscarriage at 7 weeks period (3%), six women required medical abortions due to the undeveloping pregnancy for a period of 4 to 7 weeks (18.2%). In 6% of cases (two pregnant) gestational diabetes mellitus (GDM) has been diagnosed. The average gestational age was 39.8 weeks (36–41 weeks). Preterm delivery occurred in 4 women, accounting for 15.3%. In 6% of cases (two pregnant) gestational diabetes mellitus (GDM) has been diagnosed. In total 27 children were born (in 1 case - twins), 26 (96.3%) of which at the time of birth – are healthy. The vast majority of pregnancies ended with the birth of a healthy child growth and development that did not differ from those of their peers in the general population, which corresponds to the data released by the majority of foreign researchers.Conclusions: The study confirms the absence of direct adverse effects of cabergoline (Dostinex) on the course and outcome of pregnancies in women receiving the drug at therapeutic doses before pregnancy and during the first 8 weeks of gestation.

اظهر المزيد [+]